A detailed history of Ken Griffin (Citadel Advisors LLC) transactions in Iovance Biotherapeutics, Inc. stock. As of the latest transaction made, Citadel Advisors LLC holds 327,600 shares of IOVA stock, worth $2.45 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
327,600
Previous 311,700 5.1%
Holding current value
$2.45 Million
Previous $2.5 Million 23.09%
% of portfolio
0.0%
Previous 0.0%

Shares

29 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$7.28 - $11.9 $5.68 Million - $9.29 Million
780,578 Added 320.88%
1,023,836 $9.61 Million
Q2 2024

Aug 14, 2024

SELL
$7.78 - $14.19 $6.75 Million - $12.3 Million
-867,739 Reduced 78.1%
243,258 $1.95 Million
Q1 2024

May 15, 2024

BUY
$7.59 - $17.47 $6.26 Million - $14.4 Million
824,963 Added 288.41%
1,110,997 $16.5 Million
Q4 2023

Feb 14, 2024

SELL
$3.3 - $8.89 $340,233 - $916,567
-103,101 Reduced 26.49%
286,034 $2.33 Million
Q3 2023

Nov 14, 2023

SELL
$4.44 - $8.79 $4.2 Million - $8.31 Million
-945,312 Reduced 70.84%
389,135 $1.77 Million
Q2 2023

Aug 14, 2023

SELL
$5.36 - $9.06 $11.5 Million - $19.4 Million
-2,137,584 Reduced 61.57%
1,334,447 $9.39 Million
Q1 2023

May 15, 2023

BUY
$5.53 - $8.22 $6.51 Million - $9.68 Million
1,177,989 Added 51.35%
3,472,031 $21.2 Million
Q4 2022

Feb 14, 2023

BUY
$5.62 - $10.0 $10.5 Million - $18.6 Million
1,862,210 Added 431.23%
2,294,042 $14.7 Million
Q3 2022

Nov 14, 2022

SELL
$9.53 - $13.11 $19.9 Million - $27.4 Million
-2,089,992 Reduced 82.88%
431,832 $4.14 Million
Q2 2022

Aug 15, 2022

BUY
$6.38 - $18.33 $15.2 Million - $43.7 Million
2,386,618 Added 1765.17%
2,521,824 $27.8 Million
Q1 2022

May 16, 2022

SELL
$12.38 - $19.1 $1.37 Million - $2.12 Million
-110,752 Reduced 45.03%
135,206 $2.25 Million
Q4 2021

Feb 14, 2022

SELL
$16.55 - $27.63 $18.3 Million - $30.6 Million
-1,107,605 Reduced 81.83%
245,958 $4.7 Million
Q3 2021

Nov 15, 2021

SELL
$20.35 - $26.63 $20.8 Million - $27.3 Million
-1,024,101 Reduced 43.07%
1,353,563 $33.4 Million
Q2 2021

Aug 16, 2021

BUY
$16.33 - $33.07 $26.5 Million - $53.6 Million
1,621,945 Added 214.62%
2,377,664 $61.9 Million
Q1 2021

May 17, 2021

SELL
$28.67 - $52.59 $16.3 Million - $30 Million
-570,173 Reduced 43.0%
755,719 $23.9 Million
Q4 2020

Feb 16, 2021

BUY
$28.04 - $50.26 $967,211 - $1.73 Million
34,494 Added 2.67%
1,325,892 $61.5 Million
Q3 2020

Nov 16, 2020

SELL
$27.75 - $36.3 $15.3 Million - $20 Million
-549,748 Reduced 29.86%
1,291,398 $42.5 Million
Q2 2020

Aug 14, 2020

BUY
$27.21 - $41.0 $39 Million - $58.7 Million
1,432,331 Added 350.36%
1,841,146 $50.5 Million
Q1 2020

May 15, 2020

BUY
$19.54 - $38.85 $2.01 Million - $4 Million
103,031 Added 33.69%
408,815 $12.2 Million
Q4 2019

Feb 14, 2020

BUY
$17.95 - $29.41 $3.96 Million - $6.48 Million
220,465 Added 258.4%
305,784 $8.46 Million
Q3 2019

Nov 14, 2019

SELL
$17.99 - $26.0 $3.91 Million - $5.66 Million
-217,528 Reduced 71.83%
85,319 $1.55 Million
Q2 2019

Aug 14, 2019

SELL
$9.78 - $24.52 $16 Million - $40.1 Million
-1,636,021 Reduced 84.38%
302,847 $7.43 Million
Q1 2019

May 15, 2019

SELL
$8.41 - $11.26 $20.9 Million - $28 Million
-2,488,645 Reduced 56.21%
1,938,868 $0
Q4 2018

Feb 14, 2019

BUY
$7.51 - $11.93 $8.46 Million - $13.4 Million
1,126,352 Added 34.12%
4,427,513 $39.2 Million
Q3 2018

Nov 13, 2018

BUY
$11.25 - $17.7 $32 Million - $50.3 Million
2,841,526 Added 618.21%
3,301,161 $0
Q2 2018

Aug 10, 2018

BUY
$12.45 - $16.95 $3.29 Million - $4.48 Million
264,160 Added 135.14%
459,635 $0
Q1 2018

May 11, 2018

BUY
$8.1 - $19.5 $1.32 Million - $3.19 Million
163,531 Added 511.93%
195,475 $3.3 Million
Q4 2017

Feb 09, 2018

SELL
$6.65 - $9.25 $155,477 - $216,265
-23,380 Reduced 42.26%
31,944 $256,000
Q3 2017

Nov 09, 2017

BUY
$4.45 - $8.55 $246,191 - $473,020
55,324
55,324 $429,000

Others Institutions Holding IOVA

About IOVANCE BIOTHERAPEUTICS, INC.


  • Ticker IOVA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 157,800,992
  • Market Cap $1.18B
  • Description
  • Iovance Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing cancer immunotherapy products to harness the power of a patient's immune system to eradicate cancer cells. It has six ongoing phase 2 clinical studies, including C-144-01, of its lead product candidate, lifileucel, for the treatment o...
More about IOVA
Track Ken Griffin's Portfolio

Track Ken Griffin Portfolio

Follow Ken Griffin (Citadel Advisors LLC) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.